breast-cancer-2016_posters-accepted-abstracts

Volume 8, Issue 8(Suppl)

J Cancer Sci Ther

ISSN: 1948-5956 JCST, an open access journal

Page 96

Notes:

Breast Cancer Congress 2016

September 19-21, 2016

conferenceseries

.com

Breast Cancer

September 19-21, 2016 Phoenix, USA

World Congress on

Discordance of oncotype DX score among multi-centric primary invasive cancers in the same

breast

Juskaran Chadha

Icahn School of Medicine

Background

: Presence of heterogeneity by clinico-pathologic features in multicentric primary invasive breast cancer is known.

However, the variability of 21-gene Oncotype Dx® Recurrence Score (RS) in multi-centric cancers is not well described.

Methods

: We evaluated the concordance of Oncotype Dx® RS tested on primary ipsilateral multi-centric breast cancer. From the

institutionalOncotypeDx®databaseof1304breastcancerpatients,29wereidentifiedtohave2separatepathologyspecimenstested

forRS.Nineteenpatientshadsynchronousbilateralinvasivecancers,while10patientshadipsilateralmulticentricprimaryinvasive

cancer andare the subject of this study.TheRS<18, 18-30, and>31,was categorizedas low, intermediate, andhighrisk, respectively.

TheRSof themulticentric specimenswas scored concordant if bothvalues fell in the same risk category, anddiscordant otherwise.

Results: Invasive ductal carcinoma was the most common histology. Overall RS distribution of low, intermediate and high

risk was 50%, 35% and 15%, respectively. By histologic grade (G) 1, G2, and G3, the distribution of high risk RS was 0%, 16%

and 66%, respectively. In 5 patients (50%), the RS of multi-centric cancers was discordant. Two patients had both low and

intermediate risk, 2 patients had low and high risk, and 1 patient had intermediate and high risk.

Conclusion

: The 21-gene RS notes a significant rate of discordance in primary multi-centric breast cancer. This observation

highlights the heterogeneous biology, and suggests assessing more than one sample in multi-centric disease may be a useful

strategy to guide risk-tailored cancer treatment.

Juskaran Chadha, J Cancer Sci Ther 2016, 8:8(Suppl)